Login to Your Account

Cytori looks for ECCS-50 to 'STAR' in pivotal phase III scleroderma trial

By Marie Powers
News Editor

Thursday, August 6, 2015
The first sites are screening patients in the pivotal U.S. phase III trial of ECCS-50, the adipose-derived regenerative cell (ADRC) therapy developed by Cytori Therapeutics Inc., in the lead indication of scleroderma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription